# US 2023/0382880 A1 · Gamma-hydroxybutyrate delivering compounds and processes for making and using them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0382880 A1
- Document ID: US20230382880A1
- Status: Published application
- Kind: A1
- Application number: 18/303,226
- Filed: 2023-04-19
- Published: 2023-11-30
- Earliest claimed: 2022-04-21
- Assignees: Zevra Therapeutics, Inc.
- Applicants: Zevra Therapeutics, Inc.
- Inventors: Sanjib BERA; Sven GUENTHER; Adam SMITH; Travis MICKLE
- Web page: https://patentgrep.com/patent/US20230382880A1

## CPC

- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/20: Hypnotics; Sedatives
- C07C 69/14: of monohydroxylic compounds
- C07C 69/675: of saturated hydroxy-carboxylic acids
- C07C 69/88: with esterified carboxyl groups
- C07C 69/96: Esters of carbonic or haloformic acids
- C07C 233/47: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 235/12: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 271/64: Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
- C07C 271/66: Y being a hetero atom
- C07C 301/00: Esters of sulfurous acid (cyclic esters C07D)
- C07C 305/08: Dialkylsulfates; Substituted dialkylsulfates
- C07C 307/02: Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
- C07C 307/06: having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
- C07C 311/53: X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
- C07C 333/10: having nitrogen atoms of thiocarbamic groups being part of any of the groups [IMAGE cpc-sch-C07C-0981.gif], X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 307/20: Oxygen atoms
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07F 9/09: Esters of phosphoric acids
- C07F 9/091: {with hydroxyalkyl compounds with further substituents on alkyl}
- C07F 9/224: {Phosphorus triamides}
- C07F 9/2404: {the ester moiety containing a substituent or a structure which is considered as characteristic}
- C07F 9/2458: {of aliphatic amines}
- C07F 9/2487: {containing the structure P(=X)n-N-C(=X) (X = O, S, Se; n = 0, 1)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.

## Claims

### Claim 1

A compound having a structure of Formula V:
or a pharmaceutically acceptable salt thereof;
where M is selected from the group consisting of hydrogen, 1,4-butanediol, 2-hydroxytetrahydrofuran, gamma-hydroxybutyrate, sugar alcohol, ethylene glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, lactitol, maltotriitol, maltotetraitol, polyglycitol, gamma-aminobutyric acid, phosphate, sulfate, sulfamate, alkenyl, alkenylaminocarbonyl, alkoxy, alkoxycarbonyl, alkyl, alkylamino, alkylaminocarbonyl, alkylammonium, alkylcarbonyl, alkylcarbonylamino, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkynylaminocarbonyl, amine, amino, aminocarbonyl, ammonium, aryl, substituted aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylamino, arylaminocarbonyl, arylammonium, arylazo, arylcarbonyl, arylcarbonylamino, arylcarbonyloxy, arylcycloalkyl, aryloxy, aryloxyalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylamino, arylthio, arylthioalkyl, cyano, cycloalkenyl, cycloalkenylalkyl, carboxyl, cycloalkyl, cycloalkylalkyl, cycloalkylamino, cycloalkyloxy, cycloalkynyl, cycloheteroalkyl, cycloheteroalkylalkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heteroarylamino, heteroarylcarbonyl, heteroarylcarbonylamino, heteroaryloxo, heteroaryloxy, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylthio, nitro, polycycloalkenyl, polycycloalkenylalkyl, polycycloalkyl, polycycloalkylalkyl, polyethylene glycol, thiol, amino acids, peptides, salts thereof, and combinations thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the amino acids are selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and salts thereof.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein the peptide is a dipeptide or a tripeptide.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of

### Claim 5 (depends on 1, 2, 3, 4)

A composition comprising the compound of claims 1-4, or a pharmaceutically acceptable salt of the compound, wherein the pharmaceutically acceptable salt is selected from the group consisting of an acetate, L-aspartate, besylate, bicarbonate, carbonate, D-camsylate, L-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, D-lactate, L-lactate, D,L-lactate, D,L-malate, L-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, D-tartrate, L-tartrate, D,L-tartrate, meso-tartrate, benzoate, gluceptate, D-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate, galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate, hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate, sodium, potassium, calcium, magnesium, zinc, aluminum, lithium, cholinate, lysinium, ammonium, troethamine, and a mixture thereof.

### Claim 6 (depends on 5)

A method of preventing or treating a sleep disorder or sleep syndrome in a subject in need thereof, comprising administering to the subject a composition comprising the composition of claim 5.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sleep disorder is a symptom of a degenerative neurological disease or disorder and/or is a side effect of treating a degenerative neurological disease or disorder with medication or a therapeutic compound, wherein the degenerative neurological disease or disorder is selected from the group consisting of Parkinson's disease, primary parkinsonism, paralysis agitans, and idiopathic parkinsonism.

### Claim 8 (depends on 6, 7)

The method of any one of claims 6 to 7, wherein the composition further comprises amantadine, aplindore, apomorphine, benztropine, bromocriptine, carbidopa, entacapone, fenoldopam, istradefylline, levodopa (L-dopa), opicapone, pramipexole, rasagiline, ropinirole, rotigotine, safinamide, tolcapone, trihexyphenidyl, amphetamine, armodafinil, caffeine, mazindol, methylphenidate, modafinil, pitolisant, reboxetine, samelisant, serdexmethylphenidate, solriamfetol, or combinations thereof.

### Claim 9 (depends on 6, 7, 8)

The method of any one of claims 6 to 8, wherein the sleep disorder is excessive daytime sleepiness associated with central hypersomnolence disorders, obstructive sleep apnea, or shift work disorder, wherein the central hypersomnolence disorder is selected from the group consisting of narcolepsy type-1 (with cataplexy), narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to a medical condition, hypersomnia due to a medication or substance, hypersomnia associated with a psychiatric condition, and insufficient sleep syndrome.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The composition of claim 5 or the method of any one of claims 6-9, wherein the composition further comprises one or more excipients, wherein the excipients are selected from the group consisting of anti-adherents, binders, coatings, disintegrants, fillers, flavors, dyes, colors, glidants, lubricants, preservatives, sorbents, sweeteners, derivatives thereof, and combinations thereof.

### Claim 11 (depends on 5, 6, 7, 8, 9, 10)

The composition of claim 5 or the method of any one of claims 6 to 10, composition has a dosing regimen that is about one to two times a day.

### Claim 12 (depends on 5, 6, 7, 8, 9, 10, 11)

The composition of claim 5 or the method of any one of claims 6 to 11, wherein the composition has a dosing regimen that is about one time a day, wherein the composition is orally administered to a human or an animal subject.

### Claim 13 (depends on 1, 2, 3, 4)

A kit comprising a therapeutically effective amount of a compound of any one of claims 1 to 4 or pharmaceutically acceptable salt thereof, wherein the compound is in a unit dosage form, and wherein further the unit dosage form is selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a liquid, a thin strip, an oral thin film (OTF), an oral strip, a syrup, a suspension, a slurry, a sachet, a buccal tablet, and a suppository, and instructions for use thereof.

### Claim 14 (depends on 13)

The kit of claim 13, wherein the kit further comprises an additional therapeutic compound, wherein the additional therapeutic compound is selected from the group consisting of amantadine, aplindore, apomorphine, benztropine, bromocriptine, carbidopa, entacapone, fenoldopam, istradefylline, levodopa (L-dopa), opicapone, pramipexole, rasagiline, ropinirole, rotigotine, safinamide, tolcapone, trihexyphenidyl, amphetamine, armodafinil, caffeine, mazindol, methylphenidate, modafinil, pitolisant, reboxetine, samelisant, serdexmethylphenidate, solriamfetol, and combinations thereof.

### Claim 15 (depends on 14)

The kit of claim 14, wherein the additional therapeutic compound is in a unit dosage form, wherein the unit dosage form is selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a liquid, a thin strip, an oral thin film (OTF), an oral strip, a syrup, a suspension, a slurry, a sachet, a buccal tablet, and a suppository.

### Claim 16 (depends on 1, 2, 3, 4, 15)

The kit of claim 15, wherein the compound of any one of claims 1 to 4 is in a liquid dosage form and the additional therapeutic compound is in an oral powder form or sachet form.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the additional therapeutic compound is added to the liquid dosage form of the compound prior to administration.

### Claim 18 (depends on 1, 2, 3, 4)

An oral formulation comprising a therapeutically effective dose of compound of any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The oral formulation of claim 18, wherein the oral formulation further comprises one or more excipients, wherein the excipients are selected from the group consisting of anti-adherents, binders, coatings, disintegrants, fillers, flavors, dyes, colors, glidants, lubricants, preservatives, sorbents, sweeteners, derivatives thereof, and combinations thereof.

### Claim 20 (depends on 18, 19)

The oral formulation of claim 18 or claim 19, wherein the therapeutically effective dose is in a unit dosage form, wherein the unit dosage form is selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a liquid, a thin strip, an oral thin film (OTF), an oral strip, a syrup, a suspension, a slurry, a sachet, and a buccal tablet.

### Claim 21 (depends on 18, 19, 20)

The oral formulation of any one of claims 18-20, wherein the oral formulation has a dosing regimen that is about one to two times a day.

### Claim 22 (depends on 18, 19, 20, 21)

The oral formulation of any one of claims 18 to 21, wherein the oral formulation has a dosing regimen that is about one time a day, wherein the oral formulation is orally administered to a human or an animal subject.
